Share on Facebook Share on Twitter Email
Answers.com

Batten disease

 
Neurological Disorder:

Batten disease

Definition

Batten disease is a disorder of the nervous system that begins in childhood. Symptoms of the disorder include mental impairment, seizures, and loss of sight and motor skills.

Description

Batten disease was named after the British pediatrician who first described it in 1903. The disease is characterized by an abnormal buildup of lipopigments—substances made up of fats and proteins—in bubble-like compartments within cells. The compartments, called lysosomes, normally take in and break down waste products and complex molecules for the cell. In Batten disease, this process is disrupted, and the lipopigments accumulate. This breakdown is genetic. It is marked by vision failure and the loss of intellect and neurological functions, which begin in early childhood.

Batten disease is a form of a family of progressive neurological disorders known as neuronal ceroid lipofuscinoses

(or NCLs). The disease is also known as Spielmeyer-Vogt-Sjögren-Batten disease, or juvenile NCL. There are three other disorders in the NCL family: Jansky-Bielchowsky disease, late infantile neuronal ceroid lipofuscinosis, and Kufs disease (a rare adult form of NCL). Although these disorders are often collectively referred to as Batten disease, Batten disease is a single disorder.

Demographics

Batten disease is relatively rare, occurring in two to four of every 100,000 births in the United States. NCLs appear to be more common in children living in Northern Europe and Newfoundland, Canada.

Causes and symptoms

Batten disease is an autosomal recessive disorder. This means that it occurs when a child receives one copy of the abnormal gene from each parent. Batten disease results from abnormalities in gene CLN3. This specific gene was identified by researchers in 1995.

Individuals with only one abnormal gene are known as carriers; they do not develop the disease but can pass the gene on to their own children. When both parents carry one abnormal gene, their children have a one in four chance of developing Batten disease. Early symptoms of Batten disease include vision difficulties and seizures. There may also be personality and behavioral changes, slow learning, clumsiness, or stumbling. These signs typically appear between ages five and eight. Over time, the children experience mental impairment, worsening seizures, and the complete loss of vision and motor skills.

Batten disease, like other childhood forms of NCL, may first be suspected during an eye exam that displays a loss of certain cells. Because such cell loss can occur in other eye diseases, however, the disorder cannot be diagnosed by this sign alone. An eye specialist who suspects Batten disease may refer the child to a neurologist, who will analyze the medical history and information from various laboratory tests.

Diagnosis

Diagnostic tests used for Batten disease and other NCLs include:

  • blood or urine tests that detect abnormalities that may indicate Batten disease
  • skin or tissue sampling, which can detect the buildup of lipopigments in cells
  • electroencephalogram, which displays electrical activity within the brain that suggests a person has seizures
  • electrical studies of the eyes, which further detect various eye problems common in childhood NCLs
  • brain scans, which spot changes in the brain's appearance

Treatment team

Patients suspected of having Batten disease will be diagnosed and then treated by an ophthalmologist and neurologist. Physical and occupational therapists will be consulted to help the patient maintain optimal functioning.

Treatment

There is no known treatment to prevent or reverse the symptoms of Batten disease or other NCLs. Anticonvulsant drugs are often prescribed to reduce or control seizures. Other medicines may be prescribed to manage other symptoms associated with the disorder. Physical and occupation therapy may also help people retain function for a longer period of time. Scientists' recent discovery of the genes responsible for NCLs may help lead to effective treatments.

There have been reports of the slowing of the disease among children who were given vitamins C and E and diets low in vitamin A. However, the fatal outcome of the disease remained the same.

Prognosis

People with Batten disease may become blind, confined to bed, and unable to communicate. Batten disease is typically fatal by the late teens or 20s. Some people with the disorder, however, live into their 30s.

Resources

ORGANIZATIONS

Batten Disease Support and Research Association. 2600 Parsons Ave., Columbus, OH 43207. (800) 448-4570. http://www.bdsra.org.

Children's Brain Disease Foundation. 350 Parnassus Ave., Suite 900, San Francisco, CA 94117. (415) 566-5402.

Children's Craniofacial Association. PO Box 280297, Dallas, TX 75243-4522. (972) 994-9902 or (800) 535-3643. contact cca@ccakids.com. http://www.ccakids.com.

JNCL Research Fund. PO Box 766, Mundelein, IL 60060.http://www.jnclresearch.org.

National Organization for Rare Disorders (NORD). PO Box 8923, New Fairfield, CT 06812-8923. (203) 746-6518 or (800) 999-6673. Fax: (203) 746-6481. http://www.rarediseases.org.

WEBSITES

"Batten Disease Fact Sheet." (June 2000). National Institute of Neurological Disorders and Stroke.http://www.ninds.nih.gov/health_and_medical/pubs/batten_disease.htm. "

Gene for Last Major Form of Batten Disease Discovered." (September 18, 1997). National Institute of Diabetes and Digestive and Kidney Disorders.http://www.niddk.nih.gov/welcome/releases/9_18_97.htm.


Michelle lee Brandt


Rosalyn Carson-Dewitt, MD


Search unanswered questions...
Enter a question here...
Search: All sources Community Q&A Reference topics
Wikipedia: Batten disease
Top
Batten disease
Classification and external resources
ICD-10 E75.4
ICD-9 330.1
OMIM 204200
DiseasesDB 31534
MeSH D009472

Batten disease (also known as Spielmeyer-Vogt-Sjögren-Batten disease) is a rare, fatal autosomal recessive neurodegenerative disorder that begins in childhood. It is the most common form of a group of disorders called neuronal ceroid lipofuscinosis (or NCLs).

Although Batten disease is usually regarded as the juvenile form of NCL (or "type 3"), some physicians use the term Batten disease to describe all forms of NCL. Historically, the NCLs were classified by age of disease onset as infantile NCL (INCL), late infantile NCL (LINCL), juvenile NCL (JNCL) or adult NCL (ANCL).[1]

At least nine genes have been identified in association with Batten disease, but juvenile NCL, the most prevalent form of Batten disease, has been linked to mutations in the CLN3 gene.[2][3]

Contents

Symptoms

Early symptoms of the disorder usually appear around ages 4-10, with gradual onset of vision problems, or seizures. Early signs may be subtle personality and behavior changes, slow learning or regression, repetitive speech or echolalia, clumsiness, or stumbling. There may be slowing head growth in the infantile form, poor circulation in lower extremities (legs and feet), decreased body fat and muscle mass, curvature of the spine, hyperventilation and/or breath-holding spells, teeth grinding, and constipation.

Over time, affected children suffer mental impairment, worsening seizures, and progressive loss of sight, speech and motor skills. Eventually, children with Batten disease become blind, bedridden, and demented. Batten Disease is a life limiting disease, life expectancy varies depending on the type or variation.

History

Batten disease is named after the British pediatrician Frederick Batten who first described it in 1903.[4][5] Also known as Spielmeyer-Vogt-Sjögren-Batten disease, it is the most common form of a group of disorders called neuronal ceroid lipofuscinosis (or NCLs). Although Batten disease is usually regarded as the juvenile form of NCL, some physicians use the term Batten disease to describe all forms of NCL.

Inheritance and diagnosis

Batten disease has an autosomal recessive pattern of inheritance.

Batten disease is inherited in an autosomal recessive pattern. The mutation causes the buildup of lipofuscins in the body's tissues. These substances consist of fats and proteins and form certain distinctive deposits that cause the symptoms and can be seen under an electron microscope. The diagnosis of Batten disease is based on the presence of these deposits in skin samples as well as other criteria. Six genes have now been identified that cause different types of Batten disease in children or adults, more having yet to be identified. Two of these genes encode enzymes. The function of most of these genes is still unknown. The identification of these genes opens up the possibility of gene replacement therapy or other gene-related treatments.

Treatment

In June 2004, a Phase I clinical trial was launched at Weill Medical College of Cornell University to study a gene therapy method for treatment of the signs and symptoms of late infantile neuronal ceroid lipofuscinosis (LINCL). The experimental drug works by delivering a gene transfer vector called AAV2CUhCLN2 to the brain.[6] In 2008, it was reported that the procedure, which involved injecting a harmless gene-bearing virus into the brain, is safe; and that, on average, it significantly slowed the disease's progression during the 18-month follow-up period. [7]

In November 2006, after receiving FDA clearance, neurosurgeon Dr. Nathan Selden, pediatrician Dr. Robert Steiner, and colleagues at Doernbecher Children's Hospital at Oregon Health & Science University began a clinical study in which purified neural stem cells were injected into the brain of a six-year-old child suffering from Batten disease, who had lost the ability to walk and talk. This patient was the first of six to receive the injection of a stem cell product from StemCells Inc., a Palo Alto biotech company. These are believed to be the first-ever transplants of fetal stem cells into the human brain.[8] By early December, the child had recovered well enough to return home, and it was reported that there were some signs of speech returning.[9] The main goal of Phase I clinical trials, however, was to investigate the safety of transplantation. Overall, the Phase I data demonstrated that high doses of human neural stem cells, delivered by a direct transplantation procedure into multiple sites within the brain, followed by twelve months of immunosuppression, were well tolerated by all six patients enrolled in the trial. The patients’ medical, neurological and neuropsychological conditions, following transplantation, appeared consistent with the normal course of the disease.[10]

See also

References

  1. ^ "ScienceDirect - Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease : Neuronal ceroid lipofuscinoses therapeutic strategies: Past, present and future". http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6T1Y-4KNF251-1&_user=4422&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000059600&_version=1&_urlVersion=0&_userid=4422&md5=f317b38f03a39effd5bf8be53b8d8ddd. 
  2. ^ Rakheja D, Narayan SB, Bennett MJ (September 2007). "Juvenile neuronal ceroid-lipofuscinosis (Batten disease): a brief review and update". Curr. Mol. Med. 7 (6): 603–8. doi:10.2174/156652407781695729. PMID 17896996. http://www.bentham-direct.org/pages/content.php?CMM/2007/00000007/00000006/0007M.SGM. 
  3. ^ "ScienceDirect - Experimental Neurology : Moving towards therapies for Juvenile Batten disease?". http://www.sciencedirect.com/science?_ob=ArticleURL&_udi=B6WFG-4S03RJ6-3&_user=4422&_rdoc=1&_fmt=&_orig=search&_sort=d&_docanchor=&view=c&_acct=C000059600&_version=1&_urlVersion=0&_userid=4422&md5=c5a499dbc89d656d4c3637f6c6e7c867. 
  4. ^ synd/7 at Who Named It?
  5. ^ F. E. Batten. Cerebral degeneration with symmetrical changes in the maculae in two members of a family. Transactions of the Ophthalmological Societies of the United Kingdom, 1902, 23: 386-390.
  6. ^ "Clinical Trial: Safety Study of a Gene Transfer Vector for Children With Late Infantile Neuronal Ceroid Lipofuscinosis". http://www.clinicaltrials.gov/ct/show/NCT00151216. Retrieved 2007-06-08. 
  7. ^ "Cornell Chronicle: Gene therapy for Batten D9isease". http://www.news.cornell.edu/stories/May08/wcmc.crystal.batten.html. 
  8. ^ "A stem cell first at OHSU" The Portland Tribune, Nov 24, 2006
  9. ^ http://www.technologyreview.com/read_article.aspx?id=17888&ch=biotech
  10. ^ "StemCells: Enter Date". http://www.stemcellsinc.com/news/090608.html. 

External links


 
 

 

Copyrights:

Neurological Disorder. Gale Encyclopedia of Neurological Disorders. Copyright © 2005 by The Gale Group, Inc. All rights reserved.  Read more
Wikipedia. This article is licensed under the Creative Commons Attribution/Share-Alike License. It uses material from the Wikipedia article "Batten disease" Read more